A comprehensive view of FDA Drug/Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA accepts priority review of Regeneron and Sanofi’s sBLA for Dupixent Medical dupilumab injectable to treat adults with prurigo nodularis; if approved, Dupixent would be only drug to treat prurigo nodularis in US
Published: June 08, 2022 by M2 Pharma
FDA suspends early-stage clinic trial of Vertex’s VX-880 stem-cell therapy to potentially cure type 1 diabetes for ‘insufficient information’ to approve increased dose in tests; Vertex hopes continuing studies in Canada will assuage FDA concerns
Published: May 05, 2022 by The Boston Globe
Biotech Pulse: Regeneron acquires cancer drug firm Checkmate Parmaceuticals for US$250M; Moderna reports bivent COVID-19 booster superior against Beta, Omicron variants after six months and FDA gives AstraZeneca Enhertu lung cancer drug priority review
Published: April 20, 2022 by Benzinga
Biotech Pulse: SELLA obtains right to develop and commercialize GenFleet Phase 1 cancer drug GFH009 globally outside China; Merck's pneumococcal vaccine Vaxneuvance review extended and Arca Biopharma's COVID drug rNAPc2 fails mid-stage Phase 2b study
Published: April 01, 2022 by Benzinga
AGC Biologics announces contract to manufacture materials for Phase 1 clinical trials of Allergy Therapeutics’ peanut allergy vaccine candidate; trial will commence later in 2022
Published: March 31, 2022 by AGC Biologics

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count